Latest traveler's diarrhea Stories
Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced that the company has completed enrollment in the second of two planned phase 3 clinical trials evaluating the safety and efficacy of Prulifloxacin for the treatment of infectious diarrhea in travelers.
Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced positive results from its first double-blind Phase 3 trial assessing the safety and efficacy of Prulifloxacin as a once-daily (600 mg), three-day oral therapy for infectious diarrhea.
The development of a new experimental patch could protect travelers from developing diarrhea, known as Montezumaâ€™s Revenge.
By Hanauer, Stephen B DuPont, Herbert L; Cooper, K
By Karla Gale NEW YORK (Reuters Health) - While diarrhea, fever and skin diseases still predominate among symptoms experienced by travelers to developing countries, the cause varies according to region visited, data from a large collaborative database show.